OPCH Stock Analysis: Option Care Health | NASDAQ
Medical Care Facilities | NASDAQ, USA | Market Cap: 3.382m USD | 12M Return: 13.4% | US68404L2016 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.0M
EPS Trend: 97.7%
Qual. Beats: 2
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Option Care Health, Inc. (NASDAQ: OPCH) is a U.S. provider of home and alternate site infusion services, headquartered in Bannockburn, Illinois. The company delivers intravenous and injectable therapies to patients outside of traditional hospital settings.
Its service portfolio includes anti-infective therapy, home infusion for heart failure, parenteral and enteral nutrition for conditions such as stroke, cancer, and gastrointestinal disorders, immunoglobulin therapies for immune deficiencies, and biologic treatments for chronic inflammatory diseases including Crohns disease, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. It also provides infusion therapies for neurological disorders (such as multiple sclerosis and Duchenne muscular dystrophy), bleeding disorders (including hemophilia and von Willebrand disease), high-risk pregnancies, chemotherapy, pain management, and respiratory medications, along with associated nursing services.
The company generates demand through patient referrals sourced from physicians, hospital discharge planners, hospital personnel, health maintenance organizations (HMOs), and preferred provider organizations (PPOs).
Option Care Health sits within the Health Care Services sub-industry of the broader Health Care sector. The home and alternate site infusion model allows clinically complex therapies to be delivered in lower-cost outpatient settings, a structural trend supported by payer efforts to reduce hospital admissions and length of stay.
- Home infusion demand grows with aging US population
- Medicare reimbursement changes pressure infusion service margins
- Competition from UnitedHealth and CVS specialty pharmacies intensifies
| Net Income: 209.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.14 > 1.0 |
| NWC/Revenue: 6.69% < 20% (prev 7.47%; Δ -0.78% < -1%) |
| CFO/TA 0.10 > 3% & CFO 346.8m > Net Income 209.6m |
| Net Debt (1.18b) to EBITDA (415.3m): 2.85 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (155.8m) vs 12m ago -5.09% < -2% |
| Gross Margin: 18.17% > 18% (prev 19.08%; Δ -0.91% > 0.5%) |
| Asset Turnover: 168.4% > 50% (prev 158.9%; Δ 9.55% > 0%) |
| Interest Coverage Ratio: 5.88 > 6 (EBIT TTM 343.9m / Interest Expense TTM 58.4m) |
| A: 0.11 (Total Current Assets 1.20b - Total Current Liabilities 819.5m) / Total Assets 3.38b |
| B: 0.29 (Retained Earnings 976.2m / Total Assets 3.38b) |
| C: 0.10 (EBIT TTM 343.9m / Avg Total Assets 3.38b) |
| D: 0.59 (Book Value of Equity 1.26b / Total Liabilities 2.12b) |
| Altman-Z'' = 2.99 = A |
| DSRI: 1.08 (Receivables 549.2m/481.3m, Revenue 5.69b/5.37b) |
| GMI: 1.05 (GM 19.08% / 18.17%) |
| AQI: 0.98 (AQ_t 0.60 / AQ_t-1 0.61) |
| SGI: 1.06 (Revenue 5.69b / 5.37b) |
| TATA: -0.04 (NI 209.6m - CFO 346.8m) / TA 3.38b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at USD 31.00 with a total of 65,081,516 shares traded. Over the past week, the price has changed by +35.91%, over one month by +30.58%, over three months by +45.13% and over the past year by +13.43%.
Current recommended Stop Loss: 30.10 (which is 2.9% or 1.4 ATR below the current price).
Option Care Health has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy OPCH.
- StrongBuy: 4
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.6 | -7.8% |
P/E Trailing = 16.9774
P/E Forward = 11.2233
P/S = 0.594
P/B = 2.776
P/EG = 1.1226
Revenue TTM = 5.69b USD
EBIT TTM = 343.9m USD
EBITDA TTM = 415.3m USD
Long Term Debt = 1.15b USD (from longTermDebt, last quarter)
Short Term Debt = 29.9m USD (from shortTermDebt, last quarter)
Debt = 1.38b USD (from shortLongTermDebtTotal, last quarter) + Leases 109.3m
Net Debt = 1.18b USD (calculated: Debt 1.38b - CCE 193.8m)
Enterprise Value = 4.57b USD (3.38b + Debt 1.38b - CCE 193.8m)
Interest Coverage Ratio = 5.88 (Ebit TTM 343.9m / Interest Expense TTM 58.4m)
EV/FCF = 13.16x (Enterprise Value 4.57b / FCF TTM 346.8m)
FCF Yield = 7.60% (FCF TTM 346.8m / Enterprise Value 4.57b)
FCF Margin = 6.09% (FCF TTM 346.8m / Revenue TTM 5.69b)
Net Margin = 3.68% (Net Income TTM 209.6m / Revenue TTM 5.69b)
Gross Margin = 18.17% ((Revenue TTM 5.69b - Cost of Revenue TTM 4.66b) / Revenue TTM)
Gross Margin QoQ = 18.53% (prev 18.30%)
Tobins Q-Ratio = 1.35 (Enterprise Value 4.57b / Total Assets 3.38b)
Interest Expense / Debt = 4.24% (Interest Expense 58.4m / Debt 1.38b)
Taxrate = 26.59% (75.9m / 285.5m)
NOPAT = 252.5m (EBIT 343.9m * (1 - 26.59%))
Current Ratio = 1.47 (Total Current Assets 1.20b / Total Current Liabilities 819.5m)
Debt / Equity = 1.09 (Debt 1.38b / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = 2.85 (Net Debt 1.18b / EBITDA 415.3m)
Debt / FCF = 3.41 (Net Debt 1.18b / FCF TTM 346.8m)
Total Stockholder Equity = 1.32b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.20% (Net Income 209.6m / Total Assets 3.38b)
RoE = 15.83% (Net Income TTM 209.6m / Total Stockholder Equity 1.32b)
RoCE = 13.89% (EBIT 343.9m / Capital Employed (Equity 1.32b + L.T.Debt 1.15b))
RoIC = 10.54% (NOPAT 252.5m / Invested Capital 2.40b)
WACC = 5.72% (E(3.38b)/V(4.76b) * Re(6.78%) + D(1.38b)/V(4.76b) * Rd(4.24%) * (1-Tc(0.27)))
Discount Rate = 6.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.78 | Cagr: -5.19%
[DCF] Terminal Value 77.97% ; FCFF base≈304.6m ; Y1≈349.1m ; Y5≈513.8m
[DCF] Fair Price = 43.72 (EV 7.73b - Net Debt 1.18b = Equity 6.55b / Shares 149.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.68 | EPS CAGR: 20.25% | SUE: 1.99 | # QB: 2
Revenue Correlation: 98.49 | Revenue CAGR: 13.15% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=+0.00% | Revisions=+18% | Analysts=11
EPS current Year (2026-12-31): EPS=1.88 | Chg30d=+0.00% | Revisions=+79% | GrowthEPS=+9.4% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=2.08 | Chg30d=+0.04% | Revisions=+36% | GrowthEPS=+10.7% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +55% (up=24, down=6)